NK Cell Therapy Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023

DelveInsight's, "NK Cell Therapy Pipeline Insight 2023" report provides comprehensive insights about 100+ companies and 185+ pipeline drugs in the NK Cell Therapy pipeline landscape. It covers the NK Cell Therapy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NK Cell Therapy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the NK Cell Therapy Pipeline Report
• DelveInsight's NK Cell Therapy pipeline report depicts a robust space with 100+ active players working to develop 185+ pipeline therapies for NK Cell Therapy treatment.
• The leading companies working in the NK Cell Therapy Market include ImmunityBio, Cantargia, CureTech, Dynavax, Cellid, Abivax, Affimed, Celularity, Glycostem Therapeutics (IPD Therapeutic), SYNIMMUNE, Celyad, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics, Cytovia Therapeutics, CytoImmune Therapeutics, Exacis Biotherapeutics, Novocellbio, Kuur Therapeutics (Former name: Cell Medica), Fate Therapeutics, Feldan Therapeutics, iCell Gene Therapeutics, Innate Pharma, Nkarta Therapeutics, Surface Oncology, Kiadis Pharma, Vycellix, INmune Bio, CiMass, Glycostem, Five Prime Therapeutics, Multimmune GmbH, Ambicion, Bellicum Pharmaceuticals, CARsgen therapeutics, Kuur Therapeutics, Celyad, Dragonfly Therapeutics, GamidaCell, NantKwest, Asclepius Technology Company, AffimedTherapeutics, Apceth Biopharma, Zelluna Immunotherapy, Catamaran Bio, ONK Therapeutics, Orgenesis, Navrogen, NKMAX, Nektar Therapeutics, Affimed Therapeutics, HerbiCell, Bristol-Myers Squibb, CellProtect Nordic Pharmaceuticals, CytoVac, Green Cross Corporation, NantKwest, PersonGen BioTherapeutics (Suzhou), GT Biopharma (formerly Oxis International Inc.), Nektar Therapeutics, Artiva Biotherapeutics, Senti Biosciences, oNKo-innate, Affimed Therapeutics, Agenus, Chongqing Sidemu Biotechnology, NKGen Biotech, Caribou Biosciences, Gamida-Cell, Wugen, Molmed, Century Therapeutics, KSQ Therapeutics, GT Biopharma, Shoreline Biosciences, and others.
• Promising NK Cell Therapy Pipeline Therapies in the various stages of development include Fludarabine, Cytoxan, FATE-NK100, Cetuximab, Trastuzumab, ACE1702, Cyclophosphamide, FT500, Nivolumab, Pembrolizumab, NKX019, and others.
• November 2023: Precision Biotech Taiwan Corp. announced a study of phase 1 & 2 clinical trials for Donor-derived NK cell infusion. A Phase Ι & IIa, Open-label Study to Evaluate Safety and Efficacy of the Combination Therapy of Allogeneic PB103 and Standard Cancer Treatment in the IIIB/IV or Recurrent Non-small Cell Lung Cancer (NSCLC) Patients.
• September 2023: Nkarta Inc. announced a study of Phase 1 Clinical trials for NKX019. This is a single arm, open-label, multi-center, Phase 1 study to determine the safety and tolerability of an experimental therapy called NKX019 (allogeneic CAR NK cells targeting CD19) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) or B cell acute lymphoblastic leukemia (B-ALL).
• September 2023: NKGen Biotech Inc. announced a study of Phase 1 Clinical trials for SNK02. The goal of this clinical trial is to test SNK02 in participants with pathologically confirmed cancer that is refractory to conventional therapy.

Request a sample and discover the recent advances in NK Cell Therapy Treatment Drugs @ NK Cell Therapy Pipeline Report- https://www.delveinsight.com/report-store/nk-cell-therapy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

In the NK Cell Therapy pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Natural Killer (NK) cell therapy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

NK Cell Therapy Overview
Natural killer cells, also known as NK cells are a type of lymphocytes and are key components of the innate immune system. They are highly specific predators that play a major role in the host rejection of both tumors and viral infected cells. NK cells have cytotoxic small granules, which contain special proteins such as perforins and proteases, are known as granzymes in their cytoplasm.

Find out more about NK Cell Therapy Therapeutics Assessment @ NK Cell Therapy Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/nk-cell-therapy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

NK Cell Therapy Emerging Drugs Profile
• NKTR-214: Nektar therapeutics
• Monalizumab: Innate Pharma
• Bemarituzumab: Five Prime Therapeutics
• ALT 803: ImmunityBio
• CellProtect: XNK Therapeutics
• K-NK002: Kiadis Pharma
• NK-92: ImmunityBio
• WU-NK-101: Wugen
• Anti-CD33 CAR-NK cells: PersonGen BioTherapeutics
• ALECSAT: CytoVac

NK Cell Therapy Pipeline Therapeutics Assessment
There are approx. 100+ key companies which are developing the NK Cell Therapy therapies. The NK Cell Therapy companies which have their Natural Killer (NK) cell therapy drug candidates in the most advanced stage, i.e. Phase III include, Nektar therapeutics.

Learn more about the emerging NK Cell Therapy Pipeline Therapies @ NK Cell Therapy Clinical Trials Assessment- https://www.delveinsight.com/sample-request/nk-cell-therapy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the NK Cell Therapy Pipeline Report
• Coverage- Global
• NK Cell Therapy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• NK Cell Therapy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• NK Cell Therapy Companies- ImmunityBio, Cantargia, CureTech, Dynavax, Cellid, Abivax, Affimed, Celularity, Glycostem Therapeutics (IPD Therapeutic), SYNIMMUNE, Celyad, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics, Cytovia Therapeutics, CytoImmune Therapeutics, Exacis Biotherapeutics, Novocellbio, Kuur Therapeutics (Former name: Cell Medica), Fate Therapeutics, Feldan Therapeutics, iCell Gene Therapeutics, Innate Pharma, Nkarta Therapeutics, Surface Oncology, Kiadis Pharma, Vycellix, INmune Bio, CiMass, Glycostem, Five Prime Therapeutics, Multimmune GmbH, Ambicion, Bellicum Pharmaceuticals, CARsgen therapeutics, Kuur Therapeutics, Celyad, Dragonfly Therapeutics, GamidaCell, NantKwest, Asclepius Technology Company, AffimedTherapeutics, Apceth Biopharma, Zelluna Immunotherapy, Catamaran Bio, ONK Therapeutics, Orgenesis, Navrogen, NKMAX, Nektar Therapeutics, Affimed Therapeutics, HerbiCell, Bristol-Myers Squibb, CellProtect Nordic Pharmaceuticals, CytoVac, Green Cross Corporation, NantKwest, PersonGen BioTherapeutics (Suzhou), GT Biopharma (formerly Oxis International Inc.), Nektar Therapeutics, Artiva Biotherapeutics, Senti Biosciences, oNKo-innate, Affimed Therapeutics, Agenus, Chongqing Sidemu Biotechnology, NKGen Biotech, Caribou Biosciences, Gamida-Cell, Wugen, Molmed, Century Therapeutics, KSQ Therapeutics, GT Biopharma, Shoreline Biosciences, and others.
• NK Cell Therapy Pipeline Therapies- Fludarabine, Cytoxan, FATE-NK100, Cetuximab, Trastuzumab, ACE1702, Cyclophosphamide, FT500, Nivolumab, Pembrolizumab, NKX019, and others.

Dive deep into rich insights for new drugs for NK Cell Therapy Treatment, Visit @ NK Cell Therapy Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/nk-cell-therapy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Natural Killer (NK) cell therapy: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. NKTR-214: Nektar therapeutics
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. CellProtect: XNK Therapeutics
11. Drug profiles in the detailed report…..
12. Early stage products (Phase I/II)
13. Anti-CD33 CAR-NK cells: PersonGen BioTherapeutics
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Natural Killer (NK) cell therapy Key Companies
17. Natural Killer (NK) cell therapy Key Products
18. Natural Killer (NK) cell therapy- Unmet Needs
19. Natural Killer (NK) cell therapy- Market Drivers and Barriers
20. Natural Killer (NK) cell therapy- Future Perspectives and Conclusion
21. Natural Killer (NK) cell therapy Analyst Views
22. Natural Killer (NK) cell therapy Key Companies
23. Appendix

For further information on the NK Cell Therapy Pipeline therapeutics, reach out to NK Cell Therapy Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/nk-cell-therapy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Important Published Links

https://scocial-online.mn.co/posts/46864423
https://akb.tribe.so/post/behcet-s-disease-a-rare-and-chronic-inflammatory-condition-has-long-posed-c--6576dd3288d020256754898b
https://www.sutori.com/en/denny-dones?tab=profile
https://network-96590.mn.co/posts/46865392
https://lean-in-bay-area.mn.co/posts/46865790
https://network-88594.mn.co/posts/46865905
https://decide.mn.co/posts/46866036
https://jomijomig.mn.co/posts/46866708
https://constantlycheeky.mn.co/posts/46867239
https://www.vwvortex.com/members/ybhardwaj.3957496/#about
https://redline-rp.mn.co/posts/46868784
https://forum.eset.com/profile/88964-denny-dones/?tab=field_core_pfield_11
https://en.pinkoi.com/user/gg_116344212900924579142
https://dennydones9.diary.ru/
https://slideslive.com/ewkwsgtt7o?tab=about
https://dennydones.substack.com/p/behcets-syndrome-market-size-in-the?r=33xju7&utm_campaign=post&utm_medium=web

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: +91-9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/behcets-disease-market

This release was published on openPR.